Akari Therapeutics PLC (AKTX) Stock Analysis

Akari Therapeutics PLC (AKTX) is a publicly traded company in the HEALTHCARE sector. It trades at $14.63, carries a market capitalization of $15.37M. This page summarizes the public market data, fundamentals, and frequently asked questions for AKTX, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Akari Therapeutics PLC currently has a Bullish sentiment score of 0.44.

About Akari Therapeutics PLC

Akari Therapeutics PLC is a London-based clinical-stage biopharmaceutical company focused on advancing innovative therapies for autoinflammatory diseases by targeting the complement and leukotriene pathways. With a diverse pipeline of drug candidates, Akari is dedicated to addressing considerable unmet medical needs and improving patient outcomes in this therapeutic space. The company's strategic approach, combining its scientific expertise with collaborative partnerships, positions it well t...

GNG Research Analysis

GNG Research scores Akari Therapeutics PLC (AKTX) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for AKTX.

Frequently Asked Questions

Does AKTX pay dividends?

Akari Therapeutics PLC (AKTX) does not currently pay a regular dividend.

What is AKTX's market cap?

Akari Therapeutics PLC (AKTX) has a market capitalization of $15.37M with a current stock price of $14.63.